IFNG and systemic-onset juvenile idiopathic arthritis: In addition, SJIA patients with very high IL-1 and IL-18 levels, particularly in cases of early-onset SJIA and SAM, might be good candidates for new therapeutic approaches, such as JAK inhibitors or other more experimental treatments targeting the interferon (IFN) gamma and/or IL-18 axis.